{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=11",
    "query": {
      "intervention": "Induction Phase",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 2297,
    "total_pages": 230,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Induction+Phase&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:01:55.837Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00104403",
      "title": "Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nausea and Vomiting, Chemotherapy-Induced",
        "Chemotherapy-Induced Nausea and Vomiting"
      ],
      "interventions": [
        {
          "name": "GW679769",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 722,
      "start_date": "2004-12",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2015-04-16",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00104403"
    },
    {
      "nct_id": "NCT00354913",
      "title": "Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2005-05",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354913"
    },
    {
      "nct_id": "NCT05405660",
      "title": "A Study of CDX-0159 in Patients With Chronic Inducible Urticaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Inducible Urticaria"
      ],
      "interventions": [
        {
          "name": "barzolvolimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2022-06-28",
      "completion_date": "2025-09-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Paradise Valley, Arizona + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405660"
    },
    {
      "nct_id": "NCT06809179",
      "title": "A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Social Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "Fasedienol Nasal Spray - Placebo Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Fasedienol Nasal Spray - Fasedienol Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo Nasal Spray - Placebo Nasal Spray",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VistaGen Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-01-09",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-05",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 9,
      "location_summary": "Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more",
      "locations": [
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06809179"
    },
    {
      "nct_id": "NCT04587986",
      "title": "rPMS and Radiofrequency for Abdominal Toning and Reduction of Subcutaneous Fat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fat Burn"
      ],
      "interventions": [
        {
          "name": "BTL-899",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "BTL Industries Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2019-07-30",
      "completion_date": "2021-03-16",
      "has_results": false,
      "last_update_posted_date": "2021-04-01",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 3,
      "location_summary": "River Bluff, Kentucky • Hunt Valley, Maryland • New York, New York",
      "locations": [
        {
          "city": "River Bluff",
          "state": "Kentucky"
        },
        {
          "city": "Hunt Valley",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04587986"
    },
    {
      "nct_id": "NCT02918266",
      "title": "TAK-071 Scopolamine-Induced Cognitive Impairment Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Scopolamine",
          "type": "DRUG"
        },
        {
          "name": "TAK-071",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Scopolamine Placebo",
          "type": "DRUG"
        },
        {
          "name": "TAK-071 Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2016-11-21",
      "completion_date": "2017-08-08",
      "has_results": true,
      "last_update_posted_date": "2019-06-14",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02918266"
    },
    {
      "nct_id": "NCT00940524",
      "title": "Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dasatinib, Mitoxantrone, Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2009-07",
      "completion_date": "2014-04",
      "has_results": false,
      "last_update_posted_date": "2014-04-10",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00940524"
    },
    {
      "nct_id": "NCT00273546",
      "title": "Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "XRP6976 (Docetaxel/Taxotere)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "1999-05",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2009-04-29",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273546"
    },
    {
      "nct_id": "NCT01463046",
      "title": "Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Advanced Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Panobinostat",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-01",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2019-04-22",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01463046"
    },
    {
      "nct_id": "NCT01310803",
      "title": "Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma in Situ",
        "Transitional Cell Carcinoma",
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "VALSTAR - Maintenance Therapy",
          "type": "DRUG"
        },
        {
          "name": "No Maintenance treatment ( Standard of Care)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2011-05",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-05",
      "last_synced_at": "2026-10-23T00:01:55.837Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Denver, Colorado • Cumberland, Maryland + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Cumberland",
          "state": "Maryland"
        },
        {
          "city": "Sewell",
          "state": "New Jersey"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310803"
    }
  ]
}